Aclaris Therapeutics, Inc. (ACRS) stock
ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30138% above fair value
$3.38−0.23 (-6.24%)
Close on Nov 17, 2026Market cap $497.53MP/E –Yield –
Aclaris Therapeutics cash
Cash and short-term investments held at the end of each period.
Aclaris Therapeutics's cash was $170.60M at Jun 30, 2026. For fiscal 2025 it was $151.40M, down 25.7% from the year before. Over ten years it grew 5.1% a year on average. The highest annual figure on record is $229.80M in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $151.40M | -25.7% |
| FY2024 | Dec 31, 2024 | $203.90M | +12.1% |
| FY2023 | Dec 31, 2023 | $181.90M | -20.8% |
| FY2022 | Dec 31, 2022 | $229.80M | +1.8% |
| FY2021 | Dec 31, 2021 | $225.70M | +317.2% |
| FY2020 | Dec 31, 2020 | $54.10M | -27.9% |
| FY2019 | Dec 31, 2019 | $75.02M | -55.3% |
| FY2018 | Dec 31, 2018 | $167.97M | -19.6% |
| FY2017 | Dec 31, 2017 | $208.85M | +19.9% |
| FY2016 | Dec 31, 2016 | $174.13M | +89.2% |
| FY2015 | Dec 31, 2015 | $92.04M | +470.6% |
| FY2014 | Dec 31, 2014 | $16.13M | +68.2% |
| FY2013 | Dec 31, 2013 | $9.59M | -49.7% |
| FY2012 | Dec 31, 2012 | $19.04M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $170.60M | -5.7% |
| Q1 FY2026 | Mar 31, 2026 | $190.80M | +0.2% |
| Q4 FY2025 | Dec 31, 2025 | $151.40M | -25.7% |
| Q3 FY2025 | Sep 30, 2025 | $167.20M | -3.6% |
| Q2 FY2025 | Jun 30, 2025 | $180.90M | +20.7% |
| Q1 FY2025 | Mar 31, 2025 | $190.50M | +18.0% |
| Q4 FY2024 | Dec 31, 2024 | $203.90M | +12.1% |
| Q3 FY2024 | Sep 30, 2024 | $173.40M | -7.3% |
| Q2 FY2024 | Jun 30, 2024 | $149.90M | -28.9% |
| Q1 FY2024 | Mar 31, 2024 | $161.40M | -21.0% |
| Q4 FY2023 | Dec 31, 2023 | $181.90M | -20.8% |
| Q3 FY2023 | Sep 30, 2023 | $187.00M | -24.6% |
| Q2 FY2023 | Jun 30, 2023 | $210.80M | -17.6% |
| Q1 FY2023 | Mar 31, 2023 | $204.40M | +0.4% |
| Q4 FY2022 | Dec 31, 2022 | $229.80M | +1.8% |
| Q3 FY2022 | Sep 30, 2022 | $248.10M | +1.8% |
| Q2 FY2022 | Jun 30, 2022 | $255.80M | -3.9% |
| Q1 FY2022 | Mar 31, 2022 | $203.60M | +42.7% |
| Q4 FY2021 | Dec 31, 2021 | $225.70M | +317.2% |
| Q3 FY2021 | Sep 30, 2021 | $243.60M | +341.3% |
| Q2 FY2021 | Jun 30, 2021 | $266.20M | +290.8% |
| Q1 FY2021 | Mar 31, 2021 | $142.70M | +80.6% |
| Q4 FY2020 | Dec 31, 2020 | $54.10M | -27.9% |
| Q3 FY2020 | Sep 30, 2020 | $55.20M | -39.6% |
| Q2 FY2020 | Jun 30, 2020 | $68.12M | -41.0% |
| Q1 FY2020 | Mar 31, 2020 | $79.01M | -42.2% |
| Q4 FY2019 | Dec 31, 2019 | $75.02M | -55.3% |
| Q3 FY2019 | Sep 30, 2019 | $91.43M | -31.9% |
| Q2 FY2019 | Jun 30, 2019 | $115.52M | -29.8% |
| Q1 FY2019 | Mar 31, 2019 | $136.76M | -26.9% |
| Q4 FY2018 | Dec 31, 2018 | $167.97M | -19.6% |
| Q3 FY2018 | Sep 30, 2018 | $134.27M | -41.1% |
| Q2 FY2018 | Jun 30, 2018 | $164.60M | -3.5% |
| Q1 FY2018 | Mar 31, 2018 | $186.98M | +15.8% |
| Q4 FY2017 | Dec 31, 2017 | $208.85M | +19.9% |
| Q3 FY2017 | Sep 30, 2017 | $227.85M | +171.1% |
| Q2 FY2017 | Jun 30, 2017 | $170.50M | – |
| Q1 FY2017 | Mar 31, 2017 | $161.44M | – |
| Q4 FY2016 | Dec 31, 2016 | $174.13M | – |
| Q3 FY2016 | Sep 30, 2016 | $84.04M | – |
See a number that looks wrong?